Sera Prognostics (SERA) Set to Announce Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Sera Prognostics to post earnings of ($0.22) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.08 million. During the same period last year, the firm posted ($0.34) EPS. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Price Performance

Shares of SERA stock traded up $0.28 during midday trading on Tuesday, reaching $8.23. 4,951 shares of the company traded hands, compared to its average volume of 176,017. The firm’s 50 day simple moving average is $7.36 and its two-hundred day simple moving average is $7.76. Sera Prognostics has a 1-year low of $1.65 and a 1-year high of $12.35.

Insider Buying and Selling

In related news, CEO Zhenya Lindgardt sold 12,327 shares of Sera Prognostics stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total transaction of $91,466.34. Following the completion of the transaction, the chief executive officer now directly owns 856,918 shares in the company, valued at $6,358,331.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CFO Austin Aerts sold 6,760 shares of Sera Prognostics stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total transaction of $50,159.20. Following the completion of the transaction, the chief financial officer now directly owns 303,721 shares in the company, valued at $2,253,609.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Zhenya Lindgardt sold 12,327 shares of Sera Prognostics stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total value of $91,466.34. Following the transaction, the chief executive officer now owns 856,918 shares of the company’s stock, valued at $6,358,331.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,543 shares of company stock worth $409,179 in the last ninety days. Insiders own 15.80% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.